| ID Source | ID |
|---|---|
| PubMed CID | 263211 |
| CHEMBL ID | 1490343 |
| SCHEMBL ID | 72682 |
| MeSH ID | M0382252 |
| Synonym |
|---|
| AC-13647 |
| 217968-14-4 |
| o,o'-di-p-toluoyl-d-tartaric acid |
| (2s,3s)-2,3-bis(4-methylbenzoyloxy)butanedioic acid |
| di-p-toluoyl-l-tartaric acid |
| nsc97592 |
| nsc-97592 |
| 32634-68-7 |
| (+)-o,o'-di-p-toluoyl-d-tartaric acid, made from synthetic tartaric acid, 97% |
| smr000550472 |
| MLS001165767 |
| (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid |
| AKOS000278447 |
| (+)-di-p-toluoyl-d-tartaric acid |
| D1417 |
| (+)-di-1,4-toluoyl-d-tartaric acid |
| di-p-toluoyl-d-tartaric acid |
| einecs 251-132-2 |
| butanedioic acid, 2,3-bis((4-methylbenzoyl)oxy)-, (2s,3s)- |
| unii-4480ma5qip |
| ditoluoyltartaric acid, (+)- |
| nsc 97592 |
| 4480ma5qip , |
| (s(r*,r*))-2,3-bis((4-methylbenzoyl)oxy)succinic acid |
| c20h18o8 |
| (+)-dtta |
| [s(r*,r*)]-2,3-bis[(4-methylbenzoyl)oxy]succinic acid |
| HMS2855F10 |
| (2s,3s)-2,3-bis((4-methylbenzoyl)oxy)succinic acid |
| AM20060204 |
| butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2s,3s)- |
| (+)-o,o'-di-p-toluoyl-d-tartaric acid |
| CHEMBL1490343 |
| SCHEMBL72682 |
| KS-1018 |
| d-di-o,o'-p-toluyltartaric acid |
| (+)-di-(p-toluoyl)-d-tartaric acid |
| (+)-di-o-p-toluoyl-d-tartaric acid |
| d-bis(o-4-methylbenzoyl)tartaric acid |
| (+)-ditoluoyltartaric acid |
| o,o'-di-p-toluoyl-d-tartaric acid, (+)- |
| di-p-toluoyl-d-tartaric acid, (+)- |
| di-p-toluoyl-d-tartaric acid anhydrous |
| Q-201014 |
| (2s,3s)-(+)-2,3-bis[(4-methylbenzoyl)oxy]butane-1,4-dioic acid |
| STR08702 |
| CS-W020568 |
| mfcd00008552 |
| (+)-o,o'-di-p-toluoyl-d-tartaric acid, purum, >=98.0% |
| (s,s)-o,o'-di-p-toluoyltartaric acid |
| (+)-di-p-toluoyl-d-(+)-tartaric acid |
| (+)-o,o inverted exclamation mark -di-p-toluoyl-d-tartaric acid |
| SY004755 |
| CMIBUZBMZCBCAT-HOTGVXAUSA-N |
| (2s,3s)-2,3-bis[(4-methybenzoyl)oxy]succinic acid |
| (2s,3s)-2,3-bis(4-methylbenzoyloxy)succinic acid |
| di-p-toluoyl-d-tartaricacid |
| Q27258721 |
| DTXSID80885539 |
| EN300-220735 |
| HY-Y0117 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 141.2540 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||